Clinical trials: Conduct
Lung Cancer
An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer
The purpose of this study is to evaluate the safety and tolerability of itacitinib in combination with osimertinib in subjects with locally advanced or metastatic non-small cell lung cancer (NSCLC).
- Trial name
- NCT02917993
- Testing
- Itacitinib, Osimertinib
- Where
- 31 sites in United States, South Korea and 2 more
- Volunteers
- 59 people
- Sponsor
- Incyte Corporation
Kidney Transplant Failure and Rejection
A Follow up Study of Patients Treated With Imlifidase Prior to Kidney Transplantation
The rationale for the current protocol is to collect data from extended follow up in subjects that have received a kidney transplant following imlifidase dosing to provide a better understanding regarding the long-term outcome…
- Trial name
- NCT03611621
- Testing
- Imlifidase
- Where
- 6 sites in United States, France and 1 more
- Volunteers
- 31 people
- Sponsor
- Hansa Biopharma AB
Bipolar Disorder, Bipolar Depression
Seroquel in Bipolar Depression Versus SSRI
The purpose of this study is to determine whether quetiapine is effective and safe in the acute treatment of bipolar depression and whether the effect is maintained when treatment is continued.
- Conditions
- Bipolar Disorder, Bipolar Depression, Depression
- Trial name
- EMBOLDEN II (NCT00119652)
- Testing
- quetiapine fumarate (Seroquel), paroxetine, mood stabilizing activity
- Where
- 55 sites in United States, Australia and 9 more
- Volunteers
- 676 people
- Sponsor
- AstraZeneca
Smoking
Antibody and Safety Study of 6 Doses of NicVAX in Smokers
Prior clinical trials examined several schedules of a nicotine vaccine (NicVAX) for anti-nicotine antibody responses, and their impact on helping smokers quit.
- Trial name
- NCT00598325
- Testing
- 3'-aminomethyl-Nic r-EPA Conjugate (NicVAX®)
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- Nabi Biopharmaceuticals
Multiple Sclerosis
Avonex PEN Satisfaction and Patients Experience Clinical Trial
This is an open-label, multicenter, survey-based study to determine subject satisfaction with using the single-use autoinjector for the delivery of AVONEX PS.
- Trial name
- ASPECT (NCT01366040)
- Where
- 10 sites in Canada
- Volunteers
- 89 people
- Sponsor
- Biogen
Postmenopausal Osteoporosis
Observational Study of Denosumab (Prolia®) in Postmenopausal Women With Osteoporosis
The main objective of this observational study was to describe medication-taking behavior of patients treated with denosumab for postmenopausal osteoporosis (PMO) at 12 and 24 months.
- Trial name
- NCT01668589
- Where
- 144 sites in Austria, Belgium and 2 more
- Volunteers
- 1,501 people
- Sponsor
- Amgen
Major Depressive Disorder
Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo in Major Depressive Disorder
This study is to evaluate that (SEROQUEL®) quetiapine sustained-release is efficacious and safe in the treatment of patients with MDD.
- Trial name
- MOONSTONE (NCT00320268)
- Testing
- Quetiapine fumarate
- Where
- 37 sites in United States
- Volunteers
- 600 people
- Sponsor
- AstraZeneca
Alcohol Drinking, Alcohol Use, Unspecified
Endourage Complete Spectrum Oral Mucosal Drops (OMD) in Adults Desiring a Reduction in Ethanol Use
This is the first clinical trial of Endourage OMD 1200 for persons desiring to reduce their alcohol consumption.
- Conditions
- Alcohol Drinking, Alcohol Use, Unspecified, Alcohol Abstinence, Alcohol-Related Disorders
- Trial name
- NCT04659278
- Testing
- Endourage 1200 mg OMD ™ Oral Mucosal Drops, Isolate, Peppermint Oil, masking flavor
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Endourage, LLC
Major Depressive Disorder
Open-label Safety Extension Study of 15 and 20 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults
To evaluate the long-term safety and tolerability of flexible doses, 15 and 20 mg/day, of Vortioxetine over a period of 52 weeks in patients with Major Depressive Disorder (MDD)
- Trial name
- NCT01323478
- Testing
- Vortioxetine (Lu AA21004)
- Volunteers
- 71 people
- Sponsor
- H. Lundbeck A/S
Bacterial Infections, Staphylococcal Vaccines
An Evaluation Of Three Dose Levels Of 3-Antigen Staphylococcus Aureus Vaccine (SA3Ag) In Healthy Adults
This study is a first-in-human (Phase 1) study using three dose levels of an investigational vaccine directed against Staphylococcus aureus (SA3Ag).
- Conditions
- Bacterial Infections, Staphylococcal Vaccines, Immunotherapy, Active, Staphylococcal Skin Infections
- Trial name
- NCT01018641
- Testing
- SA3Ag vaccine, Blood draw, Colonization swab samples
- Where
- 5 sites in Australia
- Volunteers
- 449 people, healthy volunteers welcome
- Sponsor
- Pfizer
Osteoarthritis, Knee, Knee Osteoarthritis
2 Weekly Intra-articular Hyaluronan Knee Injections, Given 1 wk. Apart, of HYMOVIS Combined With Physical Exercise Program (PEP) Compared to PEP Alone, in Relatively Young, Active Population of Subjects With Patellofemoral Osteoarthritis (PFOA) and/or Tibiofemoral Osteoarthritis (TFOA)
Knee osteoarthritis (OA) is among the most common causes of musculoskeletal pain and disability. At present, there is no cure for OA.
- Conditions
- Osteoarthritis, Knee, Knee Osteoarthritis, Patellofemoral Osteoarthritis
- Trial name
- NCT03281837
- Testing
- HYMOVIS plus Physical Exercise Program (PEP), Physical Exercise Program (PEP) alone
- Where
- 10 sites in United States
- Volunteers
- 148 people
- Sponsor
- Fidia Pharma USA Inc.
ADHD, ADHD - Combined Type
Phase 3 Efficacy and Safety Study in Adults With ADHD Using CTx-1301.
The goal of this clinical trial is to evaluate the efficacy and safety of CTx-1301 in adults with ADHD in a laboratory classroom setting.
- Conditions
- ADHD, ADHD - Combined Type, Attention Deficit Hyperactivity Disorder Combined, Attention Deficit Hyperactivity Disorder
- Trial name
- NCT05631626
- Testing
- CTx-1301 - Dexmethylphenidate 25mg, CTx-1301 - Dexmethylphenidate 37.5mg, CTx-1301 - Dexmethylphenidate 50mg
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Cingulate Therapeutics
ADHD
Safety and Efficacy Workplace Environment Study of Lisdexamfetamine Dimesylate (LDX) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
To evaluate the efficacy of LDX compared to placebo in adults with ADHD in the adult workplace environment (AWE) setting
- Trial name
- NCT00697515
- Testing
- LDX
- Where
- 5 sites in United States
- Volunteers
- 142 people
- Sponsor
- Shire
Infertility
A Study to Evaluate the Ease of Use, Local Tolerance, Safety and Effectiveness of Gonal-f® (Filled-by-mass in a Prefilled Pen)
This is a prospective, open-label, non-comparative, multicentric Phase 4 study to evaluate the ease of use, local tolerance, safety and effectiveness of Gonal-f® (filled-by-mass in a prefilled pen) in subjects undergoing ovarian…
- Trial name
- NCT01115725
- Testing
- Gonal-f® (follitropin alfa)
- Where
- Greece
- Volunteers
- 76 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
ADHD
Study to Assess Satisfaction With Modafinil Treatment in Children and Adolescents With ADHD
An 8-week, Open-Label Study to Characterize the Response to Modafinil (85mg Film-Coated Tablet) Treatment at Dosages up to 425mg/Day in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD) (With an…
- Trial name
- NCT00228540
- Testing
- Modafinil
- Where
- 39 sites in United States
- Sponsor
- Cephalon
Attention Deficit Hyperactivity Disorder
Atomoxetine Asian Study in Adult Subjects With Attention-Deficit/Hyperactivity Disorder (ADHD)
The primary objective of this clinical study is to assess overall safety and tolerability as measured by discontinuation rate due to adverse events in doses up to 120 mg/day in relation to global clinical studies in adult…
- Trial name
- NCT00636818
- Testing
- Atomoxetine
- Where
- 11 sites in China, South Korea and 1 more
- Volunteers
- 45 people
- Sponsor
- Eli Lilly and Company
Attention Deficit/Hyperactivity Disorder
A Trial of Centanafadine Efficacy and Safety in Children With Attention-deficit/ Hyperactivity Disorder (ADHD)
This trial will be conducted to evaluate the efficacy of centanafadine once daily (QD) extended release (XR) versus placebo in the treatment of child subjects (4 to 12 years, inclusive) with ADHD.
- Trial name
- NCT05428033
- Testing
- centanafadine capsule
- Where
- United States
- Volunteers
- 574 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Nicotine Vaping, Nicotine
Nicotine Pharmacokinetics Following Use of the P4M3 Gen 2.0 E-Cigarette Compared to Smoking Cigarettes
This is a single-center, randomized, controlled, open-label, cross-over study with healthy adult smokers. The study will investigate the nicotine pharmacokinetic (PK) profiles of two e-liquid variants used with the P4M3 Gen 2.0…
- Conditions
- Nicotine Vaping, Nicotine, Vaping
- Trial name
- NCT05383508
- Testing
- CA35, CM35, Cig
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Philip Morris Products S.A.
Major Depressive Disorder
A Clinical Trial of PRAX-114 in Participants With Major Depressive Disorder
This is a randomized, double-blind, placebo-controlled clinical trial to assess the efficacy and safety of PRAX-114 in participants with moderate to severe major depressive disorder (MDD).
- Trial name
- NCT04832425
- Testing
- PRAX-114
- Where
- 31 sites in United States, Australia
- Volunteers
- 216 people
- Sponsor
- Praxis Precision Medicines
Cognitive Wellness, Healthy Aging
MEVA Cognitive Wellness Platform Study for Adults
The goal of this observational study is to evaluate the reliability, usability, and feasibility of the MEVA Cognitive Wellness Platform in community-dwelling adults aged 55 to 75.
- Conditions
- Cognitive Wellness, Healthy Aging, Age-Related Cognitive Change, Aging
- Trial name
- MEVA (NCT07595250)
- Testing
- MEVA Cognitive Wellness Platform
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Mentage LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.